German probiotics company pushes forward with internationalization
Gräfelfing, 12.04.2022. Clinically relevant therapy options with a focus on the intestinal microbiome: SYNformulas, one of the world’s leading probiotics companies, will present its pioneering, evidence-based product range from May 10th to 12th 2022 at Vitafoods Europe on stand D84 in the Ingredients category.
With its presence at Vitafoods Europe, SYNformulas is pursuing the goal of further expanding the distribution and licensing of its products and patented bacterial strains with new business partners in order to jointly improve the quality of life of millions of people.
The scientifically approved therapy options are used for widespread diseases that can be traced back to a dysbalance of the intestinal microbiome or disorders of the intestinal barrier. An example is irritable bowel syndrome, which is estimated to affect 10-15% of the global population.
In addition to the internationally known general product portfolio of the umbrella brand Kijimea®, the mid-sized company SYNformulas is presenting its patented heat-inactivated and clinically backed bacterial strain to potential licensing partners: B. bifidum HI-MIMBb75 is exclusively contained in Kijimea® IBS PRO, which is used to treat chronical irritable bowel complaints such as diarrhoea, abdominal pain, flatulence and constipation.
The world’s largest OTC study on irritable bowel syndrome[1], published in The Lancet Gastroenterology and Hepatology, demonstrates the efficacy of B. bifidum HI-MIMBb for all symptoms of irritable bowel syndrome[2]. The bacterial strain B. bifidum MIMBb75 has also recently been included in the updated S3-guideline Irritable Bowel Syndrome[3], an independent recommendation paper for the diagnosis and treatment of irritable bowel syndrome in clinical practice.
B. bifidum HI-MIMBb75 is particularly characterized by its high mechanical and thermal stability – a quality that plays a key role for manufacturing pharmaceutical and F&B companies.
“In the European market, Kijimea® IBS PRO is already an established product and well-represented in the pharmacy range. With strong partners, we would like to further expand our international market presence and are therefore looking forward to stimulating conversations at Vitafoods Europe”, says David Rietbrock, Managing Director of SYNformulas GmbH.
Key facts SYNformulas at Vitafoods Europe 2022
Date: 10.05.- 12.05.2022
Category: Ingredients
Booth: D84
Further information about the SYNformulas trade fair appearance can be found here: https://fairs.synformulas.com/.
Appointment requests can be made via the integrated booking system.
If you have any further questions, please do not hesitate to contact our press contact.
1 Comparison only considers studies with probiotic strains.
2 Andresen V. et al. (2020). Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol Hepatol, 2020 Jul; 5(7), 658-666.
3 Layer, Andresen et al. (2021). Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie des Reizdarmsyndroms der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM). Juni 2021.
